Supplemental material
Expert Opinion on Drug Safety
Volume 23, 2024 - Issue 3
Original Research
The role of co-morbidities in the development of an AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands
, 
, &
J.W. Duijstera Vaccine Team, Netherlands Pharmacovigilance Centre Lareb, ‘s-Hertogenbosch, Netherlandshttps://orcid.org/0000-0002-9197-9079View further author information
https://orcid.org/0000-0002-9197-9079View further author information, & F.P.A.M. van Hunsela Vaccine Team, Netherlands Pharmacovigilance Centre Lareb, ‘s-Hertogenbosch, Netherlands;b Faculty of Science and Engineering, FarmacoTherapie, Epidemiologie en Economie Groningen Research Institute of Pharmacy, Groningen, the NetherlandsCorrespondence[email protected]
https://orcid.org/0000-0001-8965-3224View further author information
https://orcid.org/0000-0001-8965-3224View further author information